Elizabeth Holmes founded Theranos in 2003 on the promise that it could run hundreds of medical tests from a single drop of blood, then spent more than a decade concealing the fact that the technology never worked. What Elizabeth Holmes did, in the end, was build a $9 billion company on a product that couldn’t do what she said it could, deceive the investors who funded it, and let patients receive results generated by equipment her lab was misusing. A federal jury convicted her of wire fraud and conspiracy in January 2022, and she is now serving more than eleven years in federal prison.
The Gap Between the Pitch and the Lab
Holmes marketed a device called the Edison as a miniature laboratory capable of performing over 200 diagnostic tests, from cholesterol checks to cancer markers, using only a few drops of blood collected from a finger prick. She promised results in hours, machines small enough to sit in a pharmacy or a home, and a complete rethinking of how diagnostic medicine was delivered.
Inside the lab, almost none of that was true. Theranos ran most of its patient tests on conventional commercial analyzers made by companies like Siemens, machines designed for standard venous blood draws, not finger-prick samples. To make the small samples work on equipment built for larger volumes, staff diluted them. Dilution changes the concentration of everything being measured, and the results became unreliable. Some potassium readings came back at levels that would have meant the patient was dead. The Edison itself handled only a small fraction of the tests the company sold.
None of the technology was ever validated through independent peer-reviewed research.1PubMed Central (PMC). Lessons From Theranos – Restructuring Biomedical Innovation The company sold medical testing to the public without ever publishing evidence that it worked.
What She Told Investors
The deception that formed the basis of her criminal conviction was aimed at the people who funded Theranos. Holmes and her team produced reports that appeared to carry the endorsement of Pfizer and Schering-Plough, placing those companies’ logos on documents Theranos had written internally and sent to investors as if the pharmaceutical giants had independently validated the technology. They had not.
Financial projections were similarly invented. The SEC later alleged that Theranos overstated its projected 2014 revenue by roughly a thousand-fold compared to what the company actually earned. Holmes also told investors and business partners that Theranos devices were deployed with the U.S. military in combat zones and on medical evacuation helicopters, giving soldiers real-time diagnostics in the field. At trial, she acknowledged that Theranos devices were never used for clinical care of soldiers.
Those claims worked. The company raised more than $700 million from private investors, carried a peak valuation of roughly $9 billion in 2013 and 2014, and signed enormous commercial deals with Walgreens and Safeway on the strength of a product the company could not actually deliver.
What Happened to Patients
Patient harm is a separate strand of what Holmes did, though the jury treated it differently from the investor fraud. Real people received real test results from a lab that was diluting samples and running them on equipment that wasn’t designed for them. In May 2016, Theranos told the Centers for Medicare and Medicaid Services that it had issued tens of thousands of corrected blood-test reports to doctors and patients, voiding some results and revising others. The corrections covered roughly two years of Edison testing.
Inaccurate results can send a patient to the emergency room for a condition they don’t have, or falsely reassure someone whose cancer screening should have prompted follow-up. Thousands of medical decisions were made on data that was compromised at the point of collection.
How the Fraud Came Apart
Two employees refused to let it continue. Tyler Shultz, the grandson of board member George Shultz, saw data manipulation, false-positive syphilis results, and falsified samples during his time at the company. He raised his concerns with Holmes in April 2014, received hostile pushback from Theranos president Sunny Balwani, and resigned. Erika Cheung, a lab employee, independently identified the same problems and reported them to federal health regulators.
Both became sources for Wall Street Journal reporter John Carreyrou, whose October 16, 2015 investigation revealed that the Edison handled only a small fraction of the tests Theranos sold and that the company was secretly relying on Siemens machines. Federal inspectors followed. CMS found conditions that posed “immediate jeopardy” to patient health in the hematology department, proposed revoking the lab’s CLIA certificate, and imposed a $10,000-per-day civil penalty along with a two-year ban on the company’s owners from running any lab. Theranos shut down its lab operations and dissolved in 2018.
The SEC Settlement
Before the criminal case, the Securities and Exchange Commission reached a civil settlement with Holmes in March 2018. She paid a $500,000 penalty, returned 18.9 million shares of Theranos stock, gave up her super-majority voting control, and accepted a ten-year ban from serving as an officer or director of any public company.2U.S. Securities and Exchange Commission. Elizabeth Holmes, et al. and Ramesh Sunny Balwani The settlement stipulated that if Theranos were ever acquired or liquidated, Holmes would not profit from her remaining ownership until more than $750 million was returned to defrauded investors and other preferred shareholders.
The Criminal Conviction
Federal prosecutors indicted Holmes on wire fraud and conspiracy charges, and her trial began in late 2021 in the Northern District of California. In January 2022, the jury convicted her on three counts of wire fraud and one count of conspiracy to commit wire fraud. The wire fraud statute criminalizes using electronic communications to carry out a scheme to defraud and carries a maximum of 20 years per count.3Office of the Law Revision Counsel. 18 US Code 1343 – Fraud by Wire, Radio, or Television The conspiracy count carries the same maximum as the underlying offense.4Office of the Law Revision Counsel. 18 US Code 1349 – Attempt and Conspiracy
All four convictions involved investor fraud. The jury acquitted Holmes on the counts related to defrauding patients, finding that the government had proved intent to deceive investors but had not proved the same intent toward patients who received faulty results. Her co-defendant and former Theranos president Sunny Balwani, tried separately, was convicted on broader counts that included patient fraud and sentenced to 12 years and 11 months.
U.S. District Judge Edward Davila sentenced Holmes to 135 months in federal prison and three years of supervised release.5United States Department of Justice. Elizabeth Holmes Sentenced to More Than 11 Years for Defrauding Theranos Investors of Hundreds of Millions of Dollars The court ordered restitution of $452,047,268 to the defrauded investors, plus the standard $100 special assessment per felony count that federal law requires.6Office of the Law Revision Counsel. 18 US Code 3013 – Special Assessment on Convicted Persons
Appeal and Current Status
Holmes appealed her conviction to the Ninth Circuit. On February 24, 2025, the court affirmed the convictions, the sentence, and the $452 million restitution order, rejecting every argument she raised.7United States Courts for the Ninth Circuit. United States v Elizabeth Holmes – Opinion
She is currently incarcerated at Federal Prison Camp Bryan, a minimum-security facility in Texas about 100 miles from Houston. Her projected release date, according to Bureau of Prisons records, is August 16, 2032. Federal prosecutors have asked that during her three years of supervised release she pay at least $250 per month or 10 percent of her earnings toward restitution, whichever is greater. With a judgment of more than $452 million against her, that debt will follow her for the rest of her life.